MeSH term
Frequency | Condition_Probility | Research Support, U.S. Gov't, P.H.S. | 28 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Animals | 59 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Cytoskeleton/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Humans | 73 | 0.0 |
Mice | 20 | 0.0 |
Microtubules/*metabolism | 4 | 5.0 |
Mitosis/*drug effects | 2 | 4.0 |
Protein Binding | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 47 | 0.0 |
Time Factors | 3 | 0.0 |
Tubulin/metabolism | 2 | 2.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Antibodies/pharmacology | 2 | 0.0 |
Hela Cells | 10 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
CHO Cells | 5 | 0.0 |
Cell Line | 36 | 0.0 |
Comparative Study | 14 | 0.0 |
Hamsters | 9 | 0.0 |
Macropodidae | 21 | 84.0 |
Tubulin/*metabolism | 3 | 9.0 |
Cattle | 6 | 0.0 |
Fluorescent Dyes/*metabolism | 2 | 12.0 |
Microscopy, Fluorescence | 11 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Cells, Cultured | 17 | 0.0 |
Cytochalasin B/pharmacology | 2 | 2.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Nocodazole/pharmacology | 2 | 1.0 |
Mitosis | 4 | 0.0 |
*Photochemotherapy | 2 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Cell Cycle | 6 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Dipodomys | 3 | 42.0 |
Molecular Sequence Data | 11 | 0.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Recombinant Proteins/biosynthesis/chemistry | 2 | 2.0 |
Sequence Alignment | 3 | 0.0 |
Cricetulus | 2 | 0.0 |
Rats | 8 | 0.0 |
Mitosis/*physiology | 2 | 2.0 |
Phosphoproteins/metabolism | 4 | 0.0 |
Protein Kinases/metabolism | 2 | 0.0 |
Transfection | 6 | 0.0 |
Kinetics | 3 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Base Sequence | 5 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Aged | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Female | 14 | 0.0 |
Male | 9 | 0.0 |
Middle Aged | 4 | 0.0 |
Binding Sites | 3 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Fixatives | 2 | 2.0 |
Tubulin/immunology | 2 | 66.0 |
Epithelial Cells | 4 | 0.0 |
Fibroblasts | 2 | 0.0 |
Actins/physiology | 2 | 5.0 |
Antibody Specificity | 4 | 0.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Cell Movement/*physiology | 2 | 0.0 |
Cross Reactions | 5 | 0.0 |
Fluorescent Antibody Technique | 22 | 0.0 |
Kidney/cytology | 4 | 2.0 |
Microinjections | 3 | 1.0 |
Microscopy, Electron | 13 | 0.0 |
Microscopy, Video | 2 | 2.0 |
Paclitaxel/*pharmacology | 2 | 3.0 |
Actins/metabolism | 2 | 0.0 |
Epithelium/chemistry | 2 | 1.0 |
Dogs | 2 | 0.0 |
Adult | 5 | 0.0 |
Immunoblotting | 3 | 0.0 |
Molecular Weight | 6 | 0.0 |
Actins/*metabolism | 2 | 0.0 |
Swine | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Connective Tissue Diseases/*immunology | 3 | 23.0 |
Antibodies/immunology | 2 | 0.0 |
Polyethylene Glycols | 2 | 2.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Autoantibodies/*immunology | 4 | 1.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Calcium/*pharmacology | 2 | 2.0 |
Cell Nucleolus/*ultrastructure | 2 | 100.0 |
Anaphase/*drug effects | 2 | 100.0 |
Piperazines/*pharmacology | 2 | 3.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Centromere/*ultrastructure | 2 | 25.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Interphase | 4 | 2.0 |
Scleroderma, Systemic/immunology | 2 | 22.0 |
Alkaloids/*pharmacology | 3 | 5.0 |
Kidney | 2 | 0.0 |
Paclitaxel | 4 | 57.0 |
Vimentin/analysis | 2 | 0.0 |
Biological Transport/drug effects | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Cytoskeleton/*drug effects | 2 | 20.0 |
Microtubules/drug effects/ultrastructure | 3 | 60.0 |
Cytoskeleton/*drug effects/*ultrastructure | 2 | 100.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Longitudinal Studies | 3 | 0.0 |
Colchicine/pharmacology | 2 | 3.0 |
Cytoskeleton/*immunology | 4 | 33.0 |
Vimentin/immunology | 2 | 25.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Epitopes | 2 | 0.0 |
Immunoelectrophoresis | 2 | 0.0 |
Fibroblasts/drug effects | 2 | 2.0 |
Alkaloids/pharmacology | 2 | 1.0 |
Hela Cells/metabolism | 2 | 1.0 |
Cell Compartmentation | 2 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Demecolcine/pharmacology | 2 | 11.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Cell Nucleus/*analysis | 2 | 33.0 |
Cytoplasm/analysis | 2 | 9.0 |
Models, Biological | 2 | 0.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
